🇺🇸 FDA
Patent

US 11779603

HERV-E reactive T cell receptors and methods of use

granted A61KA61K2239/56A61K40/11

Quick answer

US patent 11779603 (HERV-E reactive T cell receptors and methods of use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2239/56, A61K40/11, A61K40/32, A61K40/46